IL17A and psoriasis: In part, this may also be favored by the treatment of psoriasis with corticosteroids or novel immunosuppressive agents such as tumor necrosis factor alpha (TNFα) or interleukin-17 (IL-17) inhibitors, as these pharmacological interventions specifically affect antifungal immune responses [11].